Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company), a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology, based on its proprietary technological platform DOS47, is pleased to announce that Mr. Praveen Varshney has been appointed as Chief Financial Officer (CFO) and Corporate Secretary. NR20240213_Appointment of New CFO
Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the voting results of the Company’s annual general and special meeting of shareholders held on January 18, 2024 (the “Meeting”). Helix Biopharma Corp. Reports […]
Helix BioPharma Corp. (TSX: “HBP”), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the 2023 fiscal year ended July 31, 2023. HELIX BIOPHARMA CORP. ANNOUNCES FISCAL 2023 YEAR-END RESULTS
Toronto, Ontario – TheNewswire – October 10, 2023 – Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), an immune-oncology antibody-drug-conjugate company developing an innovative drug platform for the treatment of cancer Helix PP Closing Aug 2023_
Angesichts hoher Inflationsraten und Zinsen raten Experten zu Value-Aktien. BORSEN-KURIER_Milliardenmarkt Krebs – Behandlung im Fokus_20230525
Nun liegen die endgültigen Inflationszahlen für den April auf dem Tisch:In der Eurozone zogen die Verbraucherpreise von zuvor 6,9 auf 7,0%an, in Österreich ging es von 9,2 auf 9,7% in die Hohe. BOERSE-EXPRESS_Helix versucht dem Krebs Saures zu geben_20230517
Kanadisches Unternehmen verweist auf vielversprechende Resultate eine Phase-1-Studie und hält nun auch in Österreich nach Investoren Ausschau DER STANDARD_Helix will mit neuem Ansatz Krebstherapie revolutionieren_20230515
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced changes in its board of directors (the “Board”) and management. Helix PP Board Changes Dec 8, 2022